These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34230073)

  • 41. Feasibility of a Scale-down Production of [
    Migliari S; Sammartano A; Scarlattei M; Baldari G; Janota B; Bonadonna RC; Ruffini L
    Curr Radiopharm; 2022; 15(1):63-75. PubMed ID: 33687908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of an
    Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
    Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
    Mi B; Xu Y; Pan D; Wang L; Yang R; Yu C; Wan W; Wu Y; Yang M
    Biochem Biophys Res Commun; 2016 Feb; 471(1):47-51. PubMed ID: 26850848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-Activity Relationships and Pharmacokinetics of
    Iikuni S; Ohara T; Watanabe H; Ono M
    Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.
    Körner M; Christ E; Wild D; Reubi JC
    Front Endocrinol (Lausanne); 2012; 3():158. PubMed ID: 23230431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
    Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
    J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [
    Otani D; Murakami T; Murakami S; Hanaoka I; Fujimoto H; Shimizu Y; Kawai Miyake K; Sakaki K; Ueda Y; Tanaka D; Ohno T; Shimizu H; Uyama N; Iizuka N; Yabe D; Nakamoto Y; Inagaki N
    Endocr J; 2024 Sep; 71(9):925-933. PubMed ID: 38839345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.
    Läppchen T; Tönnesmann R; Eersels J; Meyer PT; Maecke HR; Rylova SN
    PLoS One; 2017; 12(1):e0170435. PubMed ID: 28103285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
    Michalski K; Laubner K; Stoykow C; Omrane MA; Maecke HR; Seufert J; Goetz C; Meyer PT; Ruf J
    Clin Nucl Med; 2020 Jul; 45(7):519-524. PubMed ID: 32453080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
    Boss M; Bos D; Frielink C; Sandker G; Bronkhorst P; van Lith SAM; Brom M; Buitinga M; Gotthardt M
    J Nucl Med; 2020 Nov; 61(11):1588-1593. PubMed ID: 32385165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.
    Brom M; Joosten L; Oyen WJ; Gotthardt M; Boerman OC
    Contrast Media Mol Imaging; 2012; 7(2):160-6. PubMed ID: 22434628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.
    Pallavi UN; Malasani V; Sen I; Thakral P; Dureja S; Pant V; Gaikwad VS; Sabharwal A
    Indian J Nucl Med; 2019; 34(1):14-18. PubMed ID: 30713372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia.
    Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK
    Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
    Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.
    Wild D; Christ E; Caplin ME; Kurzawinski TR; Forrer F; Brändle M; Seufert J; Weber WA; Bomanji J; Perren A; Ell PJ; Reubi JC
    J Nucl Med; 2011 Jul; 52(7):1073-8. PubMed ID: 21680696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
    Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
    Kondo N; Oishi A; Hirata M; Temma T
    Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.